谭新华从“形精气味”论治乳腺癌相关性贫血经验
作者：
范洪桥;周亮;刘丽芳;李松莲;凌洁;...
期刊：
中国中医药信息杂志 ,2021年28(01):125-127 ISSN：1005-5304
作者机构：
湖南中医药大学第一附属医院,湖南长沙410007;[周亮; 刘丽芳; 范洪桥; 凌洁; 吴雨薇; 李松莲] 中医药大学第一附属医院
关键词：
名医经验;谭新华;乳腺癌;贫血
摘要：
本文介绍和总结谭新华教授治疗乳腺癌相关性贫血的经验。基于"形不足者温之以气,精不足者补之以味"理论,谭教授认为乳腺癌相关性贫血重要病机在于形精不足,主张从"气味"两方面补"形精"之虚,提出固形补虚、养精生血治法,可资临床借鉴。
语种：
中文
展开
谭新华从毒、瘀、虚论治银屑病经验
作者：
范洪桥;周亮;刘丽芳;王月;谭慧红;...
期刊：
中国中医药信息杂志 ,2021年28(02):115-117 ISSN：1005-5304
作者机构：
[刘丽芳; 吴世婷; 葛安琪; 谭慧红; 王月; 范洪桥; 周亮] 湖南中医药大学第一附属医院;[周立京] 湖南中医药大学
关键词：
名医经验;谭新华;伏毒;瘀血;正虚;银屑病
摘要：
本文介绍全国名老中医谭新华教授治疗银屑病的经验。谭老认为,银屑病为伏毒内蕴,毒瘀互结,损伤正气,正气亏虚,祛毒无力,伏毒伺机而发;在"治未病"思想指导下,主张其治应从"未病先防,注重养生防毒;既病防变,注重解毒化瘀;瘥后防复,注重扶正缓攻"入手,临证方可收到满意疗效。
语种：
中文
展开
Targeting Aurora B kinase with Tanshinone IIA suppresses tumor growth and overcomes radioresistance
作者：
Li, Ming;Liu, Haidan;Zhao, Qin;Han, Shuangze;Zhou, Li;...
期刊：
CELL DEATH & DISEASE ,2021年12(2):152 ISSN：2041-4889
通讯作者：
Gao, F
作者机构：
[Li, Ming; Gao, F; Liu, Haidan; Han, Shuangze; Li, Wei; Gao, Feng] Cent South Univ, Xiangya Hosp 3, Cell Transplantat & Gene Therapy Inst, Changsha 410013, Hunan, Peoples R China.;[Li, Ming; Zhao, Qin] Changsha Stomatol Hosp, Changsha 410004, Hunan, Peoples R China.;[Li, Ming; Zhao, Qin] Hunan Univ Chinese Med, Sch Stomatol, Changsha 410208, Hunan, Peoples R China.;[Li, Ming] Cent South Univ, Xiangya Stomatol Hosp, Changsha 410000, Hunan, Peoples R China.;[Li, Ming] Cent South Univ, Sch Stomatol, Changsha 410000, Hunan, Peoples R China.
通讯机构：
[Gao, F ] C;Cent South Univ, Xiangya Hosp 3, Cell Transplantat & Gene Therapy Inst, Changsha 410013, Hunan, Peoples R China.;Cent South Univ, Dept Ultrasonog, Xiangya Hosp 3, Changsha 410013, Hunan, Peoples R China.
摘要：
Aurora B kinase is aberrantly overexpressed in various tumors and shown to be a promising target for anti-cancer therapy. In human oral squamous cell carcinoma (OSCC), the high protein level of Aurora B is required for maintaining of malignant phenotypes, including in vitro cell growth, colony formation, and in vivo tumor development. By molecular modeling screening of 74 commercially available natural products, we identified that Tanshinone IIA (Tan IIA), as a potential Aurora B kinase inhibitor. The in silico docking study indicates that Tan IIA docks into the ATP-binding pocket of Aurora B, which is further confirmed by in vitro kinase assay, ex vivo pull-down, and ATP competitive binding assay. Tan IIA exhibited a significant anti-tumor effect on OSCC cells both in vitro and in vivo, including reduction of Aurora B and histone H3 phosphorylation, induction of G2/M cell cycle arrest, increase the population of polyploid cells, and promotion of apoptosis. The in vivo mouse model revealed that Tan IIA delayed tumor growth of OSCC cells. Tan IIA alone or in combination with radiation overcame radioresistance in OSCC xenograft tumors. Taken together, our data indicate that Tan IIA is an Aurora B kinase inhibitor with therapeutic potentials for cancer treatment.
语种：
英文
展开
Deguelin suppresses non-small cell lung cancer by inhibiting EGFR signaling and promoting GSK3β/FBW7-mediated Mcl-1 destabilization
作者：
Gao, Feng;Yu, Xinfang;Li, Ming;Zhou, Li;Liu, Wenbin;...
期刊：
CELL DEATH & DISEASE ,2020年11(2):143 ISSN：2041-4889
通讯作者：
Liu, HD;Li, W
作者机构：
[Liu, Haidan; Gao, Feng] Cent South Univ, Dept Cardiovasc Surg, Xiangya Hosp 2, Changsha 410011, Hunan, Peoples R China.;[Liu, Haidan; Gao, Feng] Cent South Univ, Clin Ctr Gene Diag & Therapy, Xiangya Hosp 2, Changsha 410011, Hunan, Peoples R China.;[Gao, Feng] Cent South Univ, Dept Ultrasonog, Xiangya Hosp 3, Changsha 410013, Hunan, Peoples R China.;[Yu, Xinfang] Cleveland Clin, Lerner Res Inst, Dept Canc Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.;[Li, Ming] Changsha Stomatol Hosp, Changsha 410004, Hunan, Peoples R China.
通讯机构：
[Liu, HD ; Li, W ] C;Cent South Univ, Dept Cardiovasc Surg, Xiangya Hosp 2, Changsha 410011, Hunan, Peoples R China.;Cent South Univ, Clin Ctr Gene Diag & Therapy, Xiangya Hosp 2, Changsha 410011, Hunan, Peoples R China.;Cent South Univ, Dept Radiol, Xiangya Hosp 3, Changsha 410013, Hunan, Peoples R China.
摘要：
<jats:title>Abstract</jats:title><jats:p>Activating mutations of epidermal growth factor receptor (EGFR) play crucial roles in the oncogenesis of human non-small cell lung cancer (NSCLC). By screening 79 commercially available natural products, we found that the natural compound deguelin exhibited a profound anti-tumor effect on NSCLC via directly down-regulating of EGFR-signaling pathway. Deguelin potently inhibited in vitro EGFR kinase activity of wild type (WT), exon 19 deletion, and L858R/T790M-mutated EGFR. The in silico docking study indicated that deguelin was docked into the ATP-binding pocket of EGFRs. By suppression of EGFR signaling, deguelin inhibited anchorage-dependent, and independent growth of NSCLC cell lines, and significantly delayed tumorigenesis in vivo. Further study showed that deguelin inhibited EGFR and downstream kinase Akt, which resulted in the activation of GSK3β and eventually enhanced Mcl-1 phosphorylation at S159. Moreover, deguelin promoted the interaction between Mcl-1 and E3 ligase SCF<jats:sup>FBW7</jats:sup>, which enhanced FBW7-mediated Mcl-1 ubiquitination and degradation. Additionally, phosphorylation of Mcl-1 by GSK3β is a prerequisite for FBW7-mediated Mcl-1 destruction. Depletion or pharmacological inactivation of GSK3β compromised deguelin-induced Mcl-1 ubiquitination and reduction. Taken together, our data indicate that enhancement of ubiquitination-dependent Mcl-1 turnover might be a promising approach for cancer treatment.</jats:p>
语种：
英文
展开
从“阴极阳衰”治疗乳腺癌
作者：
范洪桥;刘丽芳;周亮
期刊：
中国中医基础医学杂志 ,2020年26(12):1873-1875 ISSN：1006-3250
作者机构：
湖南中医药大学第一附属医院乳腺科, 长沙 410007;[周亮; 刘丽芳; 范洪桥] 中医药大学第一附属医院
关键词：
阴极阳衰;乳腺癌;温阳法
摘要：
介绍与总结乳腺癌的治疗思路与方法。笔者认为乳腺癌发生的根本病机在于“阴极阳衰”、阳气亏虚、“阳化气”功能不足,寒凝、痰饮、瘀血、癌毒等“阴成形”太过。随着这些有形之阴邪的不断积聚,阻滞于乳络而发为乳腺癌,并由此提出温阳法是乳腺癌的治疗大法,温阳以扶正,温阳以抑阴。同时审详标实之候,综合运用温阳行气解郁、温阳化痰散结、温阳活血化瘀、温阳清解癌毒、温阳调摄冲任等法,以期收到标本兼顾、温阳不留邪、祛邪即扶正的目的,并列举临床验案一则,以飨同道。
语种：
中文
展开
谭新华治疗乳腺癌骨转移经验撷菁
作者：
范洪桥;周亮;刘丽芳;吴雨薇;谭新华
期刊：
中国中医基础医学杂志 ,2020年26(8):1175-1176,1182 ISSN：1006-3250
作者机构：
湖南中医药大学第一附属医院乳腺科,长沙 410007;湖南中医药大学研究生院,长沙 410208;[周亮; 刘丽芳; 范洪桥; 谭新华] 中医药大学第一附属医院;[吴雨薇] 湖南中医药大学
关键词：
乳腺癌;骨转移;名医经验;谭新华
摘要：
总结介绍谭新华教授治疗乳腺癌骨转移的经验,认为乳腺癌骨转移的基本病机为阴极阳衰,因素体阳气亏虚,气化功能下降,痰瘀毒等阴性产物聚结凝聚于骨,“虚”“痰”“瘀”“毒”夹杂合而为病。主张以温阳抑阴为治疗大法,温阳化气促使“阳化气”功能得到正常发挥,减少“阴成形”功能失调所产生的痰瘀毒等病理产物,常选用阳和汤为基本方进行加减治疗。临证时首先注重权衡虚实标本轻重主次,灵活处理益气扶正药物与化痰散结、活血祛瘀、化解癌毒等祛邪药物的比例。再兼以虫蚁类搜剔定痛、破瘀通经,参以引经之药引领众药直达病所,方可收到满意疗效。
语种：
中文
展开
刘丽芳治疗浆细胞性乳腺炎用药规律
作者：
周亮;范洪桥;刘丽芳;王月;葛安琪;...
期刊：
河南中医 ,2020年(09):1348-1351 ISSN：1003-5028
作者机构：
湖南中医药大学第一附医院
关键词：
浆细胞性乳腺炎;肿块期;刘丽芳;数据挖掘;用药规律
摘要：
目的:运用数据挖掘技术分析刘丽芳教授治疗浆细胞性乳腺炎的用药规律。方法:收集整理刘教授2013年1月至2018年1月于湖南中医药大学第一附属医院乳腺科门诊治疗的浆细胞性乳腺炎患者的医案。将筛选后的数据录入软件,建立方药数据库,并进行数据分析,探讨刘教授治疗浆细胞性乳腺炎的常用药物及药物组合规律。结果:共纳入处方4 670首,涉及药物123味,高频药物组合40组,关联规则40条,核心药物组合20组,提炼核心处方10首。常用药物为蒲公英、金银花、醋柴胡、海藻、醋莪术、醋鳖甲、醋三棱与昆布等。结论:刘丽芳教授治疗浆细胞性乳腺炎重视肝气郁滞,痰瘀凝聚成块,郁久化热的病机,以疏肝清热、化痰散结、活血消肿为治疗大法。
语种：
中文
展开
Xanthohumol targets the ERK1/2-Fra1 signaling axis to reduce cyclin D1 expression and inhibit non-small cell lung cancer
作者：
Gao, Feng;Li, Ming;Zhou, Li;Liu, Wenbin;Zuo, Huilan;...
期刊：
ONCOLOGY REPORTS ,2020年44(4):1365-1374 ISSN：1021-335X
通讯作者：
Li, W
作者机构：
[Li, Ming; Zuo, Huilan; Li, Wei; Gao, Feng] Cent South Univ, Xiangya Hosp 3, Cell Transplantat & Gene Therapy Inst, Changsha 410013, Hunan, Peoples R China.;[Zuo, Huilan; Gao, Feng] Cent South Univ, Xiangya Hosp 3, Dept Ultrasonog, Changsha 410013, Hunan, Peoples R China.;[Li, Ming] Changsha Stomatol Hosp, Changsha 410004, Hunan, Peoples R China.;[Li, Ming] Hunan Univ Chinese Med, Sch Stomatol, Changsha 410208, Hunan, Peoples R China.;[Zhou, Li] Cent South Univ, Xiangya Hosp, Dept Pathol, Changsha, Peoples R China.
通讯机构：
[Li, W ] C;Cent South Univ, Xiangya Hosp 3, Dept Radiol, 138 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China.
关键词：
cyclin D1;messenger RNA;mitogen activated protein kinase 1;transcription factor Fra 1;xanthohumol;CCND1 protein, human;cyclin D1;flavonoid;propiophenone derivative;protein c fos;transcription factor Fra 1;xanthohumol;animal experiment;animal model;animal tissue;antineoplastic activity;Article;cancer inhibition;clinical article;controlled study;down regulation;drug mechanism;gene mutation;human;human cell;human tissue;in vitro study;in vivo study;MAPK signaling;mouse;non small cell lung cancer;nonhuman;priority journal;protein degradation;protein expression;protein expression level;protein phosphorylation;ubiquitination;animal;cell proliferation;drug effect;drug screening;gene expression regulation;genetics;MAPK signaling;non small cell lung cancer;pathology;signal transduction;tumor cell line;Animals;Carcinoma, Non-Small-Cell Lung;Cell Line, Tumor;Cell Proliferation;Cyclin D1;Flavonoids;Gene Expression Regulation, Neoplastic;Humans;MAP Kinase Signaling System;Mice;Propiophenones;Proto-Oncogene Proteins c-fos;Signal Transduction;Xenograft Model Antitumor Assays
摘要：
High expression of cyclin D1 has a crucial role in the maintenance of unlimited cell growth in human cancer cells. The present study indicated that cyclin D1 was overexpressed in human non-small cell lung cancer (NSCLC) tumor tissues and cell lines. Knockout of cyclin D1 suppressed NSCLC cell growth, colony formation and in vivo tumor growth. Of note, the natural product xanthohumol (Xanth) inhibited NSCLC cells via the downregulation of cyclin D1. A further mechanistic study revealed that Xanth suppressed ERK1/2 signaling and reduced the protein levels of FOS-related antigen 1 (Fra1), which eventually inhibited the transcriptional activity of activator protein-1 and decreased the mRNA level of cyclin D1. Furthermore, suppression of ERK1/2 impaired Fra1 phosphorylation and enhanced Xanth-induced Fra1 ubiquitination and degradation. In addition, the S265D mutation compromised Xanth-induced Fra1 degradation. Finally, the in vivo anti-tumor effect of Xanth was validated in a xenograft mouse model. In summary, the present results indicated that targeting ERK1/2-Fra1-cyclin D1 signaling is a promising anti-tumor strategy for NSCLC treatment. © This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.
语种：
英文
展开
刘丽芳治疗浆细胞性乳腺炎用药规律分析
作者：
周亮;王月;李松莲;罗君
期刊：
中医药导报 ,2020年26(13):102-106 ISSN：1672-951X
作者机构：
湖南中医药大学第一附属医院,湖南长沙410007;湖南中医药大学,湖南长沙410208;[王月; 周亮] 中医药大学第一附属医院;[罗君; 李松莲] 湖南中医药大学
关键词：
浆细胞性乳腺炎;中医辨证;分期论治;刘丽芳;用药规律;数据挖掘
摘要：
目的:分析浆细胞性乳腺炎中医用药规律,为该病临床治疗提供参考。方法:选取2013年1月至2018年1月我院乳腺科刘丽芳门诊6个月内痊愈的浆细胞性乳腺炎患者处方,对肿块期、脓肿期、瘘管期中药处方进行药物频数及功效分类频数统计,并对处方用药进行关联规则挖掘及处方药味网络分析。结果:清热解毒类药物用量较多出现在脓肿期,行气活血类药物用量较多出现在肿块期,健脾益气类药物用量较多出现在脓肿期和溃脓期,温阳类药物用量较多出现在肿块期。肿块期置信度最高的关联药物是:醋莪术,昆布→海藻;网络核心药物组成:醋紫胡、蒲公英、金银花、海藻、昆布、醋三棱、醋莪术、醋鳖甲。脓肿期置信度最高的关联药物是:蒲公英、茯苓、黄芪、金银花→白术;网络核心药物组成:茯苓、黄芪、当归、白芷、醋鳖甲、白术、蒲公英、皂角刺、川芎、陈皮、金银花。瘘管期置信度最高的关联药物是:川芎,茯苓,金银花,当归→白术;网络核心药物组成:茯苓、皂角刺、白芷、蒲公英、白术、当归、金银花、川芎。结论:"清、散"之法贯穿整个治疗过程,肿块期少佐温阳类药物,脓肿期结合益气健脾之法以托毒透脓,瘘管期结合益气健脾之法以托里散结。
语种：
中文
展开
Traditional Chinese Medicine Combined With Chemotherapy and Cetuximab or Bevacizumab for Metastatic Colorectal Cancer: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
作者：
Liu, Ningning;Wu, Chaojun;Jia, Ru;Cai, Guoxiang;Wang, Yan;...
期刊：
Frontiers in Pharmacology ,2020年11:511606 ISSN：1663-9812
通讯作者：
Li, Qi
作者机构：
[Li, Qi; Liu, Ningning; Ji, Qing; Wu, Chaojun; Deng, Wanli; Wang, Yan; Feng, Yuanyuan; Zhou, Lihong; Sui, Hua; Jia, Ru] Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Dept Med Oncol, Shanghai, Peoples R China.;[Li, Qi; Liu, Ningning; Wu, Chaojun; Jia, Ru] Shanghai Univ Tradit Chinese Med, Acad Integrat Med, Shanghai, Peoples R China.;[Cai, Guoxiang] Fudan Univ, Dept Colorectal Canc Surg, Shanghai Canc Ctr, Shanghai, Peoples R China.;[Zeng, Puhua] Hunan Acad Tradit Chinese Med, Canc Res Inst, Changsha, Peoples R China.;[Xiao, Haijuan] Shaanxi Univ Chinese Med, Dept Oncol, Hosp Affiliated, Xianyang, Peoples R China.
通讯机构：
[Li, Qi] S;Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Dept Med Oncol, Shanghai, Peoples R China.;Shanghai Univ Tradit Chinese Med, Acad Integrat Med, Shanghai, Peoples R China.
关键词：
cetuximab (CET) or bevacizumab (BV);metastatic colorectal cancer;progression-free survival;quality of life;traditional Chinese medicine
摘要：
Background: Huangci Granule is a traditional Chinese medicine for treating metastatic colorectal cancer (mCRC). Objective: To evaluate the efficacy and safety of Huangci Granule combination with chemotherapy and cetuximab (CET) or bevacizumab (BV) for treating mCRC. Methods: We performed a randomized, controlled, and double-blind trial and recruited patients with mCRC who were planned to undergo chemotherapy combined with CET or BV. The treatment group was treated with Huangci Granule, while the control group was treated with placebo. Continuous treatment until disease progression, death, intolerable toxicity or up to 6 months. The primary endpoint was progression-free survival (PFS), and the secondary endpoint was quality of life and safety. Result: 320 patients were randomly assigned to receive treatment, including 200 first-line patients and 120 second-line patients. In the first-line treatment, the median PFS was 9.59 months (95% CI, 6.94–13.25) vs 6.89 months (95% CI, 4.99–9.52) in treatment group and control group (HR, 0.69; 95% CI, 0.50–0.97; P = 0.027). Chinese medicine was an independent factor affecting the PFS. In the second-line treatment, the median PFS was 6.51 months (95% CI, 4.49–9.44) vs 4.53 months (95% CI, 3.12–6.57) in the treatment group and control group (HR, 0.65; 95% CI, 0.45–0.95; P = 0.020). Compared with the control group, “role function,” “social function,” “fatigue,” and “appetite loss” were significantly improved in the treatment (P < 0.05) and drug related grades 3 to 4 adverse events were less. Conclusion: Huangci Granule combined with chemotherapy and CET or BV can prolong the PFS of mCRC, improve the quality of life, reduce adverse reactions, and have good safety. © Copyright © 2020 Liu, Wu, Jia, Cai, Wang, Zhou, Ji, Sui, Zeng, Xiao, Liu, Huo, Feng, Deng and Li.
语种：
英文
展开
刘丽芳教授从“气化”理论论治乳腺癌肺转移经验
作者：
范洪桥;周亮;王月;谭慧红;吴世婷;...
期刊：
中医药学报 ,2020年48(08):37-40 ISSN：1002-2392
作者机构：
湖南中医药大学第一附属医院乳腺科,湖南 长沙410007;[葛安琪; 王月; 周亮; 范洪桥; 吴世婷; 李松莲; 谭慧红] 中医药大学第一附属医院
关键词：
气化;乳腺癌;肺转移;名医经验
摘要：
文章介绍和总结刘丽芳教授治疗乳腺癌肺转移的临证经验。刘教授在"气化"理论的指导下,认为阳气亏虚,气化功能失司为发病之根本,痰瘀毒结于肺络为发病之标实。治疗上强调温阳以助气化,喜用阳和汤为基本方加减,并主张温阳之法贯穿于乳腺癌肺转移治疗的整个过程,再综合分析痰饮、瘀血、癌毒等标实之邪,综合运用温阳化痰散结、温阳活血化瘀、温阳抗癌解毒等法。同时善用引经之药,以直达病所。附以验案一则,以飨同道。
语种：
中文
展开
刘丽芳从阴疽理论治疗肉芽肿性乳腺炎经验
作者：
范洪桥;周亮;刘丽芳;凌洁;周笛;...
期刊：
辽宁中医杂志 ,2020年47(9):31-33 ISSN：1000-1719
作者机构：
湖南中医药大学第一附属医院乳腺科,湖南长沙410007;湖南中医药大学研究生院,湖南长沙410208;[周亮; 刘丽芳; 范洪桥] 中医药大学第一附属医院;[周笛; 凌洁; 吴雨薇] 湖南中医药大学
关键词：
刘丽芳;肉芽肿性乳腺炎;阴疽;名医经验
摘要：
介绍和总结刘丽芳教授治疗肉芽肿性乳腺炎经验。刘丽芳教授据其临床特点,如皮肤紫黯或颜色不变、皮温不高、疮形平塌漫肿、血多于脓、溃疡紫黯、病程较长等,认为本病属于阴证,与阴疽的病机特点十分类似,二者病机为阳气亏虚,痰瘀互结,阳气不足为病之本,风寒湿邪侵袭,气血阻滞,痰瘀互结是病之标。主张用温阳法治疗本病,温阳可使阴寒、痰凝、瘀阻等病理产物得以正常气化,使其逐渐得以温化而消散。喜用阳和汤为基本方治其本。同时审详标实之候,综合运用温阳行气解郁、温阳化痰散结、温阳活血化瘀、温阳清热解毒等法,以期收到标本兼顾,温阳不留邪,祛邪即扶正的目的。并附以临床验案,以飨同道。
语种：
中文
展开
谭新华治疗乳腺癌术后上肢淋巴水肿经验
作者：
范洪桥;刘丽芳;周亮;谭新华(指导)
期刊：
中国中医药信息杂志 ,2020年27(2):126-128 ISSN：1005-5304
作者机构：
湖南中医药大学第一附属医院,湖南长沙410007;湖南中医药大学研究生院,湖南长沙410208;[周亮; 刘丽芳] 湖南中医药大学;[范洪桥] 中医药大学第一附属医院
关键词：
名医经验;谭新华;淋巴水肿;乳腺癌
摘要：
本文介绍谭新华教授治疗乳腺癌术后上肢淋巴水肿的经验。谭老认为,乳腺癌术后上肢淋巴水肿的基本病机为正气亏虚,毒瘀内结,瘀血化水。治以益气活血为主,兼搜风通络,参以引经药直达病所;并强调需权衡虚实轻重主次,主张内服与外治相结合,方可收到较好疗效。
语种：
中文
展开
矾冰纳米乳加压封包治疗哺乳期乳腺脓肿的临床观察
作者：
周亮;刘丽芳;王月
期刊：
中医药导报 ,2020年26(7):59-60+73 ISSN：1672-951X
作者机构：
湖南中医药大学第一附属医院,湖南长沙410007;[王月; 周亮; 刘丽芳] 中医药大学第一附属医院
关键词：
矾冰纳米乳;哺乳期;乳腺脓肿;加压封包;微创负压引流技术
摘要：
目的:探讨矾冰纳米乳加压封包结合微创负压置管引流技术治疗哺乳期乳腺脓肿的疗效.方法:将160例哺乳期乳腺脓肿患者随机分为对照组与治疗组,每组80例.两组均采用微创负压引流手术治疗,治疗组予矾冰纳米乳湿纱布加压封包,对照组采用普通无菌纱布加压包扎.观察两组患者每天引流管内引流液的多少、留置引流管天数、伤口平均痊愈时间、治疗期间生活质量评分及疼痛评分.结果:治疗组总有效率高于对照组,差异有统计学意义(P＜0.05);治疗组患者伤口愈合时间短于对照组,差异有统计学意义(P＜0.05);治疗组患者治疗期间生活质量评分高于对照组、疼痛评分低于对照组,差异均有统计学意义(P＜0.05).结论:微创负压引流技术联合矾冰纳米乳湿纱布加压封包治疗乳腺脓肿的治疗效果好,伤口愈合时间短.
语种：
中文
展开
Inhibition of erks/akt-mediated c-fos expression is required for piperlongumine-induced cyclin D1 downregulation and tumor suppression in colorectal cancer cells
作者：
Gao, Feng;Zhou, Li;Li, Ming;Liu, Wenbin;Yang, Shuting;...
期刊：
ONCOTARGETS AND THERAPY ,2020年13:5591-5603 ISSN：1178-6930
通讯作者：
Li, W
作者机构：
[Li, Ming; Liu, Wenbin; Li, Wei; Gao, Feng] Cent South Univ, Xiangya Hosp 3, Cell Transplantat & Gene Therapy Inst, Changsha 410013, Hunan, Peoples R China.;[Yang, Shuting; Gao, Feng] Cent South Univ, Dept Ultrasonog, Xiangya Hosp 3, Changsha 410013, Hunan, Peoples R China.;[Zhou, Li] Cent South Univ, Dept Pathol, Xiangya Hosp, Changsha 410013, Hunan, Peoples R China.;[Li, Ming] Changsha Stomatol Hosp, Changsha 410004, Hunan, Peoples R China.;[Li, Ming] Hunan Univ Chinese Med, Sch Stomatol, Changsha 410208, Hunan, Peoples R China.
通讯机构：
[Li, W ] C;Cent South Univ, Xiangya Hosp 3, Cell Transplantat & Gene Therapy Inst, Changsha 410013, Hunan, Peoples R China.;Cent South Univ, Dept Radiol, Xiangya Hosp 3, Changsha 410013, Hunan, Peoples R China.
关键词：
antineoplastic agent;cyclin D1;histone H3;messenger RNA;mitogen activated protein kinase;mitogen activated protein kinase 1;mitogen activated protein kinase 3;piperlongumine;protein c fos;protein kinase B;transcription factor AP 1;unclassified drug;Akt signaling;animal experiment;animal model;animal tissue;antineoplastic activity;Article;bioassay;cancer inhibition;cancer tissue;carcinogenesis;cell cycle;cell growth;colony formation;colorectal cancer;colorectal cancer cell line;controlled study;Cyclin D1 gene;down regulation;enzyme activation;enzyme inhibition;female;flow cytometry;gene overexpression;half life time;histone phosphorylation;human;human cell;human tissue;immunoblotting;immunofluorescence;immunohistochemistry;in vivo study;MAPK signaling;mouse;mouse model;nonhuman;protein degradation;protein expression;protein function;reverse transcription polymerase chain reaction;tissue level;transcription regulation;tumor xenograft;ubiquitination
摘要：
Background: Deregulation of Cyclin D1 and cell cycle progression plays a critical role in tumorigenesis. The natural compound piperlongumine (PL) exhibits potential anticancer effects in various cancer models, but the underlying mechanism needs further elucidation. Methods: The inhibitory effect of PL on colorectal cancer (CRC) cells was determined by anchorage-dependent and-independent assays. The protein level of Cyclin D1 was examined by immunoblot (IB) and immunohistochemical staining (IHC). The mRNA level was determined by qRT-PCR. Phosphorylation of histone H3 was analyzed by immunofluorescence (IF). The cell cycle was examined by flow cytometry. The in vivo antitumor effect was validated by the xenograft mouse model. Results: Cyclin D1 was overexpressed in CRC tissues and cells, and was required for maintaining cell growth, colony formation, and in vivo tumorigenesis. PL decreased the protein level of c-Fos, which eventually reduced the transcriptional activity of AP-1 and the mRNA level of Cyclin D1. Mechanism study showed that PL impaired EGF-induced activation of ERK1/2 and Akt signalings, which resulted in a reduction of c-Fos transcription. Furthermore, PL reduced the half-life of c-Fos and caused the ubiquitination-dependent degradation of c-Fos. Finally, the in vivo antitumor effect of PL on CRC cells was examined using a xenograft mouse model. Conclusion: Our data indicate that PL is a promising antitumor agent that deserves further study for CRC treatment. © 2020 Gao et al.
语种：
英文
展开
刘丽芳治疗非哺乳期乳腺炎溃后期经验
作者：
刘慧;周亮;胡金辉;葛安琪;凌洁;...
期刊：
湖南中医药大学学报 ,2020年40(12):1483-1487 ISSN：1674-070X
作者机构：
湖南中医药大学第一附属医院,湖南 长沙 410007;湖南中医药大学,湖南 长沙 410208;[胡金辉; 葛安琪; 周亮; 刘丽芳; 刘慧] 中医药大学第一附属医院;[凌洁] 湖南中医药大学
关键词：
非哺乳期乳腺炎;煨脓生肌;托里消毒散;九华膏;刘丽芳
摘要：
非哺乳期乳腺炎因其反复成脓,溃后易形成窦道、瘘管,迁延难治.刘丽芳教授认为该病后期痰湿蒸酿肉腐成脓,溃后成瘘.溃后期内治调补气血,外治煨脓生肌,并重视康复期巩固调摄.临床运用托里消毒散联合九华膏等,内治与外治相结合,可防止窦道、瘘管的形成,缩短了该类病的治疗时间,疗效显著.
语种：
中文
展开
基于数据挖掘的刘丽芳教授治疗乳腺导管瘘用药处方规律分析
作者：
王月;周亮;刘丽芳;范洪桥
期刊：
湖南中医药大学学报 ,2020年40(3):360-363 ISSN：1674-070X
作者机构：
湖南中医药大学第一附属医院,湖南长沙410007;[王月; 周亮; 刘丽芳; 范洪挢] 中医药大学第一附属医院
关键词：
乳腺导管瘘;中药;数据挖掘;刘丽芳;用药规律
摘要：
目的 分析刘丽芳教授治疗乳腺导管瘘的临床用药配伍规律.方法 整理收集刘丽芳教授治疗乳腺导管瘘2011年1月至2017年6月的门诊处方,运用“中医传承辅助平台(v2.5)”软件进行数据挖掘,对所选处方用药频次、药物关联规则、组方规律、核心处方、新处方进行分析.结果 共纳入处方3 723首,高频药物组合54组,出现频率最高的为“蒲公英-白术”、“蒲公英-金银花(济银花)”.确定药物之间关联规则,进行统计分析后获得药物核心组合20个,得到新处方10个.结论 刘丽芳教授治疗乳腺导管瘘以清热解毒、消肿散结为核心治则,注重疏肝和胃,并结合甘苦合化法,化痰燥湿、行气活血等治法分期论治.
语种：
中文
展开
基于数据挖掘分析刘丽芳教授治疗浆细胞性乳腺炎的用药规律
作者：
周亮;范洪桥;王月;葛安琪;李松莲;...
期刊：
湖南中医药大学学报 ,2020年40(5):587-591 ISSN：1674-070X
作者机构：
湖南中医药大学第一附医院乳腺科,湖南 长沙410007;[葛安琪; 王月; 周亮; 罗君; 范洪桥; 李松莲] 中医药大学第一附属医院
关键词：
浆细胞性乳腺炎;刘丽芳;用药规律;数据挖掘
摘要：
目的分析刘丽芳教授治疗浆细胞性乳腺炎的用药特点及治疗规律,为临床治疗提供参考。方法追踪与整理刘教授2013年1月-2018年1月于湖南中医药大学第一附属医院乳腺科门诊治疗的浆细胞性乳腺炎有效医案。将收集到的有效医案按肿块期、脓肿期、瘘管期进行分类,将筛选后的数据录入软件,建立方药数据库。运用数据挖掘软件对浆细胞性乳腺炎的处方用药进行大数据分析,证、法、方、药进行关联规则挖掘,并结合中医药理论对统计结果进行分析。结果肿块期核心处方:蒲公英-金银花-土贝母-醋鳖甲-连翘-柴胡-海藻-炒芥子-白术;脓肿期核心处方:蒲公英-金银花-白术-皂角刺-连翘-土贝母-黄芪-炒麦芽;瘘管期核心处方:蒲公英-金银花-连翘-黄芪-皂角刺-土贝母-白术-醋鳖甲-炒芥子等。结论肿块期高频药物以清、散+温为主,补益类药物用量很少;脓肿期以清、散+补为主,温阳类药物用量很少;瘘管期以清、散+补益类少佐温阳类药物。三个阶段用药各具特色,总体以"清热解毒、活血化痰散结"为主,兼以"温化、补益"为其主要用药特点。
语种：
中文
展开
从“血不利则为水”论乳腺癌术后上肢淋巴水肿的中医证治
作者：
范洪桥;刘丽芳;周亮;李松莲
期刊：
时珍国医国药 ,2020年31(03):657-659 ISSN：1008-0805
作者机构：
湖南中医药大学第一附属医院,湖南长沙410007;湖南中医药大学研究生院,湖南长沙410208;[周亮; 刘丽芳; 范洪桥] 中医药大学第一附属医院;[李松莲] 湖南中医药大学
关键词：
血不利则为水;乳腺癌;淋巴水肿;中医中药
摘要：
文章探讨乳腺癌术后上肢淋巴水肿的中医证治。认为乳腺癌术后上肢淋巴水肿的病机在于\"血不利则为水\",因\"血\"而病\"水\"。若细思忖,深究其根源,\"血不利\"乃引起水肿病的中间环节,\"为水\"是\"血不利\"的病理产物,\"血不利\"与\"为水\"产生的根本原因在于气病,在于阳的化气功能低下。主张以益气温阳治其本,温阳抑阴,促阳化气,兼以行气活血、利水消肿治其标,\"气\"\"血\"\"水\"同治,希冀达到\"气化则血行,血利则水消\"的目的。
语种：
中文
展开
刘丽芳教授治疗结节性红斑经验
作者：
范洪桥;刘丽芳;周亮;王月;谭慧红;...
期刊：
四川中医 ,2020年38(04):18-19 ISSN：1000-3649
作者机构：
湖南中医药大学第一附属医院,湖南 长沙 410007;[葛安琪; 王月; 周亮; 刘丽芳; 范洪桥; 吴世婷; 谭慧红; 刘慧] 中医药大学第一附属医院
关键词：
鸡鸣散;刘丽芳;结节性红斑;名医经验
摘要：
文章介绍和总结刘丽芳教授治疗结节性红斑的临证经验。认为阳气亏虚,尤其是肾阳不足为其病机之本,湿瘀郁而化毒为其病机关键。治疗上急性期强调温阳化湿活血,透解毒邪;缓解期注重调理肺肝脾肾以治本;善用引经之药,以直达病所;注重内外合治,标本兼顾,以收痊愈之功。附以验案一则,以飨同道。
语种：
中文
展开
